增殖细胞核抗原在淋巴结阴性人前列腺癌中的表达
Expression of proliferating cell nuclear antigen in node-negative human prostate cancer.
作者信息
Idikio H A
机构信息
Department of Laboratory Medicine and Pathology, University of Alberta, Canada.
出版信息
Anticancer Res. 1996 Sep-Oct;16(5A):2607-11.
Cancer cell proliferation could be an important predictor of clinical behavior and survival in node-negative prostate cancers. Proliferating cell nuclear antigen (PCNA; PC10) immunostaining was determined in 38 prostate biopsies and transurethral resections in clinically organ confined prostate cancers. 14 of the prostate cancers were Gleason score 2-4 and 24 were Gleason score 5-7. 29 were stage T2 and 9 were stage T3. Gleason score 2-4 cancers had a mean PCNA of 7.08 (s.d 5.1); Gleason score 5-7 had a mean PCNA of 11.42 (s.d 7.7), Stage T2 cancers had a mean PCNA of 8.007 (s.d 6.13) and stage T3 cancers had a mean PCNA of 12.7 (s.d 8.49). 21.4% of Gleason score 2-4, 12.5% of Gleason score 5-7, 10.7% of stage T2 and 10% of stage T3 had mean PCNA counts of twice their mean values. 4/24 (16.67%) of Gleason score 5-7 and 28.57% of stage T3 cancers had total PCNA counts > 20/2hpf suggesting high counts are indices of progression.
癌细胞增殖可能是临床行为和淋巴结阴性前列腺癌生存的重要预测指标。在38例临床局限于器官的前列腺癌的前列腺活检和经尿道切除标本中，检测增殖细胞核抗原（PCNA；PC10）免疫染色。其中14例前列腺癌Gleason评分为2-4分，24例为Gleason评分5-7分。29例为T2期，9例为T3期。Gleason评分2-4分的癌症患者PCNA平均为7.08（标准差5.1）；Gleason评分5-7分的患者PCNA平均为11.42（标准差7.7），T2期癌症患者PCNA平均为8.007（标准差6.13），T3期癌症患者PCNA平均为12.7（标准差8.49）。Gleason评分2-4分的患者中21.4%、Gleason评分5-7分的患者中12.5%、T2期患者中10.7%以及T3期患者中10%的PCNA平均计数是其平均值的两倍。Gleason评分5-7分的患者中有4/24（16.67%）以及T3期癌症患者中有28.57%的PCNA总计数>20/2hpf，提示高计数是进展的指标。
Zotero 插件